Skip to content

Study · Randomized controlled trial · n = 183 · 2013

3 results

Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial.

Song G, Gao H, Yuan Z

Medical oncology (Northwood, London, England)1 Aug 2013Cited by 51 (Europe PMC)

PMID23904400 (opens in a new tab)DOI10.1007/s12032-013-0667-8 (opens in a new tab)PepBankPUB-23904400
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal breast cancer patients, menses resumed in 15 patients with added leuprolide versus 27 with chemotherapy only.

    In plain wordsIn breast cancer patients, menses resumed in 15 patients with added leuprolide versus 27 with chemotherapy only.

    Peptide
    Leuprolide
    Outcome
    DecreaseResumption of menses
    Study

    n = 183

    Comparator
    Chemotherapy only
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Patients who resumed menses
    15 patients
    chemotherapy plus leuprolide acetate group, 89 evaluable
    Patients who resumed menses
    27 patients
    chemotherapy-only group, 94 evaluable

    Source sentences

    Summary
    At the end of follow-up, 27 patients in chemotherapy group and 15 in chemotherapy plus leuprolide acetate group resumed menses;
    2 context sentences
    Summary · context
    A total of 220 patients were recruited in this prospective clinical trial and were assigned randomly to receive cyclophosphamide-doxorubicin-based chemotherapy only or chemotherapy plus leuprolide acetate.
    Summary · context
    A total of 183 patients were considered evaluable (94 in chemotherapy-only group and 89 in chemotherapy plus leuprolide acetate group).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In breast cancer patients, premenopausal FSH and E2 returned in 14 patients with added leuprolide versus seven with chemotherapy only.

    In plain wordsIn breast cancer patients, hormone levels returned to premenopausal levels in 14 patients with added leuprolide versus seven with chemotherapy only.

    Peptide
    Leuprolide
    Outcome
    IncreaseRestoration of premenopausal FSH and E2
    Study

    n = 183

    Comparator
    Chemotherapy only
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Patients who restored premenopausal FSH and E2
    14 patients
    chemotherapy plus leuprolide acetate group, 89 evaluable
    Patients who restored premenopausal FSH and E2
    7 patients
    chemotherapy-only group, 94 evaluable

    Source sentences

    Summary
    seven patients in chemotherapy group and 14 in chemotherapy plus leuprolide acetate group restored premenopausal levels of FSH and E2.
    2 context sentences
    Summary · context
    A total of 220 patients were recruited in this prospective clinical trial and were assigned randomly to receive cyclophosphamide-doxorubicin-based chemotherapy only or chemotherapy plus leuprolide acetate.
    Summary · context
    A total of 183 patients were considered evaluable (94 in chemotherapy-only group and 89 in chemotherapy plus leuprolide acetate group).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In breast cancer patients, median time to menses resumption was 9.2 months with added leuprolide and not reached with chemotherapy only.

    In plain wordsIn breast cancer patients, median time to menses return was 9.2 months with added leuprolide and not reached with chemotherapy only.

    Peptide
    Leuprolide
    Outcome
    DecreaseTime to menses resumption
    Study

    n = 183

    Comparator
    Chemotherapy only
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Median time to resume menses
    9.2 months
    chemotherapy plus leuprolide acetate group; not reached in chemotherapy-only group

    Source sentences

    Summary
    The median time to resume menses was 9.2 months for patients in chemotherapy plus leuprolide acetate group and was not reached in chemotherapy-only group.
    2 context sentences
    Summary · context
    A total of 220 patients were recruited in this prospective clinical trial and were assigned randomly to receive cyclophosphamide-doxorubicin-based chemotherapy only or chemotherapy plus leuprolide acetate.
    Summary · context
    A total of 183 patients were considered evaluable (94 in chemotherapy-only group and 89 in chemotherapy plus leuprolide acetate group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.